{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:37:51Z","timestamp":1791185871778,"version":"4.1.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,2,25]],"date-time":"2011-02-25T00:00:00Z","timestamp":1298592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,2,25]],"date-time":"2011-02-25T00:00:00Z","timestamp":1298592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1038\/leu.2011.7","type":"journal-article","created":{"date-parts":[[2011,2,25]],"date-time":"2011-02-25T09:40:24Z","timestamp":1298626824000},"page":"761-769","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells"],"prefix":"10.1038","volume":"25","author":[{"given":"L F","family":"Peterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Mitrikeska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Giannola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Bixby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S N","family":"Malek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N J","family":"Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Talpaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,25]]},"reference":[{"key":"BFleu20117_CR1","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1172\/JCI31771","volume":"117","author":"PC Nowell","year":"2007","unstructured":"Nowell PC . Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest 2007; 117: 2033\u20132035.","journal-title":"J Clin Invest"},{"key":"BFleu20117_CR2","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/35106108","volume":"1","author":"JD Rowley","year":"2001","unstructured":"Rowley JD . Chromosome translocations: dangerous liaisons revisited. Nat Rev Cancer 2001; 1: 245\u2013250.","journal-title":"Nat Rev Cancer"},{"key":"BFleu20117_CR3","first-page":"1460","volume":"21","author":"U Matulonis","year":"1993","unstructured":"Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD . Interleukin-3 and p210 BCR\/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol 1993; 21: 1460\u20131466.","journal-title":"Exp Hematol"},{"key":"BFleu20117_CR4","doi-asserted-by":"publisher","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","volume":"16","author":"T Skorski","year":"1997","unstructured":"Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK et al. Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3k\/Akt-dependent pathway. EMBO J 1997; 16: 6151\u20136161.","journal-title":"EMBO J"},{"key":"BFleu20117_CR5","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.1038\/sj.onc.1205942","volume":"21","author":"S Xie","year":"2002","unstructured":"Xie S, Lin H, Sun T, Arlinghaus RB . Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene 2002; 21: 7137\u20137146.","journal-title":"Oncogene"},{"key":"BFleu20117_CR6","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1084\/jem.183.3.811","volume":"183","author":"N Carlesso","year":"1996","unstructured":"Carlesso N, Frank DA, Griffin JD . Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl. J Exp Med 1996; 183: 811\u2013820.","journal-title":"J Exp Med"},{"key":"BFleu20117_CR7","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1158\/1078-0432.CCR-06-2320","volume":"13","author":"D Perrotti","year":"2007","unstructured":"Perrotti D, Neviani P . From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way. Clin Cancer Res 2007; 13: 1638\u20131642.","journal-title":"Clin Cancer Res"},{"key":"BFleu20117_CR8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0092-8674(03)00190-9","volume":"112","author":"M Azam","year":"2003","unstructured":"Azam M, Latek RR, Daley GQ . Mechanisms of autoinhibition and STI-571\/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003; 112: 831\u2013843.","journal-title":"Cell"},{"key":"BFleu20117_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","volume":"4","author":"CB Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L . Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75\u201385.","journal-title":"Lancet Oncol"},{"key":"BFleu20117_CR10","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nrc2012","volume":"6","author":"F Toledo","year":"2006","unstructured":"Toledo F, Wahl GM . Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6: 909\u2013923.","journal-title":"Nat Rev Cancer"},{"key":"BFleu20117_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1634\/theoncologist.5-5-405","volume":"5","author":"A Di Bacco","year":"2000","unstructured":"Di Bacco A, Keeshan K, McKenna SL, Cotter TG . Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis. Oncologist 2000; 5: 405\u2013415.","journal-title":"Oncologist"},{"key":"BFleu20117_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1535-6108(03)00020-5","volume":"3","author":"R Trotta","year":"2003","unstructured":"Trotta R, Vignudelli T, Candini O, Intine RV, Pecorari L, Guerzoni C et al. BCR\/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell 2003; 3: 145\u2013160.","journal-title":"Cancer Cell"},{"key":"BFleu20117_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrm2147","volume":"8","author":"KH Vousden","year":"2007","unstructured":"Vousden KH, Lane DP . p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275\u2013283.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFleu20117_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.colsurfb.2006.11.003","volume":"55","author":"K-X Shu","year":"2007","unstructured":"Shu K-X, Li B, Wu L-X . The p53 network: p53 and its downstream genes. Colloids Surfaces B Biointerfaces 2007; 55: 10\u201318.","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"BFleu20117_CR15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nrm2395","volume":"9","author":"T Riley","year":"2008","unstructured":"Riley T, Sontag E, Chen P, Levine A . Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9: 402\u2013412.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFleu20117_CR16","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1182\/blood-2008-05-156380","volume":"112","author":"AJ Steele","year":"2008","unstructured":"Steele AJ, Prentice AG, Hoffbrand AV, Yogashangary BC, Hart SM, Nacheva EP et al. p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. Blood 2008; 112: 3827\u20133834.","journal-title":"Blood"},{"key":"BFleu20117_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1097-2765(03)00050-9","volume":"11","author":"M Mihara","year":"2003","unstructured":"Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11: 577\u2013590.","journal-title":"Mol Cell"},{"key":"BFleu20117_CR18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/ncb1123","volume":"6","author":"JIJ Leu","year":"2004","unstructured":"Leu JIJ, Dumont P, Hafey M, Murphy ME, George DL . Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004; 6: 443\u2013450.","journal-title":"Nat Cell Biol"},{"key":"BFleu20117_CR19","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844\u2013848.","journal-title":"Science"},{"key":"BFleu20117_CR20","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1073\/pnas.0708917105","volume":"105","author":"S Shangary","year":"2008","unstructured":"Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008; 105: 3933\u20133938.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu20117_CR21","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1021\/jm051122a","volume":"49","author":"K Ding","year":"2006","unstructured":"Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S, Shangary S et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2&. J Med Chem 2006; 49: 3432\u20133435.","journal-title":"J Med Chem"},{"key":"BFleu20117_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev.pharmtox.48.113006.094723","volume":"49","author":"S Shangary","year":"2009","unstructured":"Shangary S, Wang S . Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009; 49: 223.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"BFleu20117_CR23","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1182\/blood-2007-09-112698","volume":"111","author":"C Saddler","year":"2008","unstructured":"Saddler C, Ouillette P, Kujawski L, Shangary S, Talpaz M, Kaminski M et al. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008; 111: 1584\u20131593.","journal-title":"Blood"},{"key":"BFleu20117_CR24","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1126\/science.1068999","volume":"296","author":"TR Brummelkamp","year":"2002","unstructured":"Brummelkamp TR, Bernards R, Agami R . A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550\u2013553.","journal-title":"Science"},{"key":"BFleu20117_CR25","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.immuni.2006.03.018","volume":"24","author":"NL Alves","year":"2006","unstructured":"Alves NL, Derks IAM, Berk E, Spijker R, van Lier RAW, Eldering E . The Noxa\/Mcl-1 axis regulates susceptibility to apoptosis under glucose limitation in dividing T cells. Immunity 2006; 24: 703\u2013716.","journal-title":"Immunity"},{"key":"BFleu20117_CR26","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1038\/sj.leu.2404849","volume":"21","author":"LF Peterson","year":"2007","unstructured":"Peterson LF, Wang Y, Lo MC, Yan M, Kanbe E, Zhang DE . The multi-functional cellular adhesion molecule CD44 is regulated by the 8;21 chromosomal translocation. Leukemia 2007; 21: 2010\u20132019.","journal-title":"Leukemia"},{"key":"BFleu20117_CR27","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1038\/sj.leu.2402576","volume":"16","author":"K Keeshan","year":"2002","unstructured":"Keeshan K, Cotter TG, McKenna SL . High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion. Leukemia 2002; 16: 1725\u20131734.","journal-title":"Leukemia"},{"key":"BFleu20117_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.molmed.2006.11.002","volume":"13","author":"LT Vassilev","year":"2007","unstructured":"Vassilev LT . MDM2 inhibitors for cancer therapy. Trends Mol Med 2007; 13: 23\u201331.","journal-title":"Trends Mol Med"},{"key":"BFleu20117_CR29","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1023\/A:1016119328968","volume":"7","author":"C Soldani","year":"2002","unstructured":"Soldani C, Scovassi AI . Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002; 7: 321\u2013328.","journal-title":"Apoptosis"},{"key":"BFleu20117_CR30","doi-asserted-by":"crossref","first-page":"22925","DOI":"10.1016\/S0021-9258(17)31596-X","volume":"269","author":"T Oda","year":"1994","unstructured":"Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ . Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia. J Biol Chem 1994; 269: 22925\u201322928.","journal-title":"J Biol Chem"},{"key":"BFleu20117_CR31","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/sj.onc.1210707","volume":"27","author":"LM Lau","year":"2008","unstructured":"Lau LM, Nugent JK, Zhao X, Irwin MS . HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008; 27: 997\u20131003.","journal-title":"Oncogene"},{"key":"BFleu20117_CR32","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1182\/blood-2006-02-005579","volume":"109","author":"GA Bartholomeusz","year":"2007","unstructured":"Bartholomeusz GA, Talpaz M, Kapuria V, Kong LY, Wang S, Estrov Z et al. Activation of a novel Bcr\/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells. Blood 2007; 109: 3470\u20133478.","journal-title":"Blood"},{"key":"BFleu20117_CR33","doi-asserted-by":"publisher","first-page":"3303","DOI":"10.1182\/blood-2004-02-0749","volume":"105","author":"KJ Aichberger","year":"2005","unstructured":"Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K et al. Identification of mcl-1 as a BCR\/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 2005; 105: 3303\u20133311.","journal-title":"Blood"},{"key":"BFleu20117_CR34","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.cell.2008.11.010","volume":"135","author":"JF Lovell","year":"2008","unstructured":"Lovell JF, Billen LP, Bindner S, Shamas-Din A, Fradin C, Leber B et al. Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by bax. Cell 2008; 135: 1074\u20131084.","journal-title":"Cell"},{"key":"BFleu20117_CR35","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.4161\/cc.7.11.5929","volume":"7","author":"M Xia","year":"2008","unstructured":"Xia M, Knezevic D, Tovar C, Huang B, Heimbrook DC, Vassilev LT . Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation. Cell Cycle 2008; 7: 1604\u20131612.","journal-title":"Cell Cycle"},{"key":"BFleu20117_CR36","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/blood.V101.2.690","volume":"101","author":"NJ Donato","year":"2003","unstructured":"Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690\u2013698.","journal-title":"Blood"},{"key":"BFleu20117_CR37","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1084\/jem.188.11.2033","volume":"188","author":"M Muller","year":"1998","unstructured":"Muller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M et al. p53 activates the CD95 (APO-1\/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998; 188: 2033\u20132045.","journal-title":"J Exp Med"},{"key":"BFleu20117_CR38","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nrm2434","volume":"9","author":"Y-LP Ow","year":"2008","unstructured":"Ow Y-LP, Green DR, Hao Z, Mak TW . Cytochrome c: functions beyond respiration. Nat Rev Mol Cell Biol 2008; 9: 532\u2013542.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFleu20117_CR39","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bbabio.2008.10.005","volume":"1787","author":"AV Vaseva","year":"2009","unstructured":"Vaseva AV, Moll UM . The mitochondrial p53 pathway. Biochim Biophys Acta (BBA)\u2014Bioenergetics 2009; 1787: 414\u2013420.","journal-title":"Biochim Biophys Acta (BBA)\u2014Bioenergetics"},{"issue":"S1","key":"BFleu20117_CR40","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1038\/onc.2009.46","volume":"27","author":"C Ploner","year":"2009","unstructured":"Ploner C, Kofler R, Villunger A . Noxa: at the tip of the balance between life and death. Oncogene 2009; 27 (S1): S84\u2013S92.","journal-title":"Oncogene"},{"key":"BFleu20117_CR41","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood.V89.3.957","volume":"89","author":"C Selleri","year":"1997","unstructured":"Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett AJ, Rotoli B et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood 1997; 89: 957\u2013964.","journal-title":"Blood"},{"key":"BFleu20117_CR42","doi-asserted-by":"publisher","first-page":"838","DOI":"10.4161\/cc.8.6.7906","volume":"8","author":"I Sancho-Martinez","year":"2009","unstructured":"Sancho-Martinez I, Martin-Villalba A . Tyrosine phosphorylation and CD95: a FAScinating switch. Cell Cycle 2009; 8: 838\u2013842.","journal-title":"Cell Cycle"},{"key":"BFleu20117_CR43","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1476-4598-9-161","volume":"9","author":"E Ametller","year":"2010","unstructured":"Ametller E, Garcia-Recio S, Costamagna D, Mayordomo C, Fernandez-Nogueira P, Carbo N et al. Tumor promoting effects of CD95 signaling in chemoresistant cells. Mol Cancer 2010; 9: 161.","journal-title":"Mol Cancer"},{"key":"BFleu20117_CR44","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1182\/blood-2008-07-077958","volume":"112","author":"BJ Druker","year":"2008","unstructured":"Druker BJ . Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112: 4808\u20134817.","journal-title":"Blood"},{"key":"BFleu20117_CR45","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O'Hare","year":"2007","unstructured":"O'Hare T, Eide CA, Deininger MW . Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007; 110: 2242\u20132249.","journal-title":"Blood"},{"key":"BFleu20117_CR46","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","volume":"22","author":"NP Shah","year":"2003","unstructured":"Shah NP, Sawyers CL . Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003; 22: 7389\u20137395.","journal-title":"Oncogene"},{"key":"BFleu20117_CR47","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1080\/10428190701665988","volume":"48","author":"L Kujawski","year":"2007","unstructured":"Kujawski L, Talpaz M . Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leuk Lymphoma 2007; 48: 2310\u20132322.","journal-title":"Leuk Lymphoma"},{"key":"BFleu20117_CR48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319\u2013325.","journal-title":"Blood"},{"key":"BFleu20117_CR49","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","volume":"109","author":"HG Jorgensen","year":"2007","unstructured":"Jorgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL . Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007; 109: 4016\u20134019.","journal-title":"Blood"},{"key":"BFleu20117_CR50","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","volume":"107","author":"M Copland","year":"2006","unstructured":"Copland M, Hamilton A, Elrick LJ, Baird JW, Allan EK, Jordanides N et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107: 4532\u20134539.","journal-title":"Blood"},{"key":"BFleu20117_CR51","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1600-0609.1996.tb01369.x","volume":"57","author":"B Seliger","year":"1996","unstructured":"Seliger B, Papadileris S, Vogel D, Hess G, Brendel C, Storkel S et al. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. Eur J Haematol 1996; 57: 230\u2013240.","journal-title":"Eur J Haematol"},{"key":"BFleu20117_CR52","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1182\/blood-2007-03-078303","volume":"110","author":"JS Chang","year":"2007","unstructured":"Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E et al. High levels of the BCR\/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C\/EBP alpha-driven myeloid differentiation. Blood 2007; 110: 994\u20131003.","journal-title":"Blood"},{"key":"BFleu20117_CR53","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2005-09-3732","volume":"107","author":"M Notari","year":"2006","unstructured":"Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A et al. A MAPK\/HNRPK pathway controls BCR\/ABL oncogenic potential by regulating MYC mRNA translation. Blood 2006; 107: 2507\u20132516.","journal-title":"Blood"},{"key":"BFleu20117_CR54","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1182\/blood-2007-05-090472","volume":"111","author":"AM Eiring","year":"2008","unstructured":"Eiring AM, Neviani P, Santhanam R, Oaks JJ, Chang JS, Notari M et al. Identification of novel posttranscriptional targets of the BCR\/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR\/ABL leukemogenesis. Blood 2008; 111: 816\u2013828.","journal-title":"Blood"},{"key":"BFleu20117_CR55","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1038\/sj.onc.1207494","volume":"23","author":"EA Komarova","year":"2004","unstructured":"Komarova EA, Kondratov RV, Wang K, Christov K, Golovkina TV, Goldblum JR et al. Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene 2004; 23: 3265\u20133271.","journal-title":"Oncogene"},{"key":"BFleu20117_CR56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.stem.2008.11.006","volume":"4","author":"Y Liu","year":"2009","unstructured":"Liu Y, Elf SE, Miyata Y, Sashida G, Huang G, Di Giandomenico S et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 2009; 4: 37\u201348.","journal-title":"Cell Stem Cell"},{"key":"BFleu20117_CR57","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nature06869","volume":"453","author":"OO Akala","year":"2008","unstructured":"Akala OO, Park I-K, Qian D, Pihalja M, Becker MW, Clarke MF . Long-term haematopoietic reconstitution by Trp53\u2212\/\u2212p16Ink4a\u2212\/\u2212p19Arf\u2212\/\u2212 multipotent progenitors. Nature 2008; 453: 228\u2013232.","journal-title":"Nature"},{"key":"BFleu20117_CR58","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1182\/blood-2005-08-3273","volume":"107","author":"L Coll-Mulet","year":"2006","unstructured":"Coll-Mulet L, Iglesias-Serret D, Santidrian AF, Cosialls AM, de Frias M, Castano E et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006; 107: 4109\u20134114.","journal-title":"Blood"},{"key":"BFleu20117_CR59","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530\u20133539.","journal-title":"Blood"},{"key":"BFleu20117_CR60","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928\u20131937.","journal-title":"Blood"},{"key":"BFleu20117_CR61","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1056\/NEJMoa040258","volume":"351","author":"CH Jamieson","year":"2004","unstructured":"Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657\u2013667.","journal-title":"N Engl J Med"},{"key":"BFleu20117_CR62","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1073\/pnas.0900189106","volume":"106","author":"AE Abrahamsson","year":"2009","unstructured":"Abrahamsson AE, Geron I, Gotlib J, Dao K-HT, Barroga CF, Newton IG et al. Glycogen synthase kinase 3\u03b2 missplicing contributes to leukemia stem cell generation. Proc Natl Acad Sci USA 2009; 106: 3925\u20133929.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu20117_CR63","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ccr.2007.11.003","volume":"12","author":"C Zhao","year":"2007","unstructured":"Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM et al. Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007; 12: 528\u2013541.","journal-title":"Cancer Cell"},{"key":"BFleu20117_CR64","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/nature07737","volume":"458","author":"C Zhao","year":"2009","unstructured":"Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009; 458: 776\u2013779.","journal-title":"Nature"},{"key":"BFleu20117_CR65","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/emboj.2009.16","volume":"28","author":"B Stecca","year":"2009","unstructured":"Stecca B, Ruiz i Altaba A . A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. EMBO J 2009; 28: 663\u2013676.","journal-title":"EMBO J"},{"key":"BFleu20117_CR66","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/pros.20660","volume":"67","author":"A Prowald","year":"2007","unstructured":"Prowald A, Cronauer MV, von Klot C, Eilers T, Rinnab L, Herrmann T et al. Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53. Prostate 2007; 67: 1751\u20131760.","journal-title":"Prostate"},{"key":"BFleu20117_CR67","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1038\/sj.onc.1207464","volume":"23","author":"K Rother","year":"2004","unstructured":"Rother K, Johne C, Spiesbach K, Haugwitz U, Tschop K, Wasner M et al. Identification of Tcf-4 as a transcriptional target of p53 signalling. Oncogene 2004; 23: 3376\u20133384.","journal-title":"Oncogene"},{"key":"BFleu20117_CR68","doi-asserted-by":"publisher","first-page":"4838","DOI":"10.1073\/pnas.0712216105","volume":"105","author":"Y Abe","year":"2008","unstructured":"Abe Y, Oda-Sato E, Tobiume K, Kawauchi K, Taya Y, Okamoto K et al. Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2. Proc Natl Acad Sci USA 2008; 105: 4838\u20134843.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu20117_CR69","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2010-01-261628","volume":"116","author":"J Long","year":"2010","unstructured":"Long J, Parkin B, Ouillette P, Bixby D, Shedden K, Erba H et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood 2010; 116: 71\u201380.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu20117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu20117","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu20117.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:19:17Z","timestamp":1648736357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu20117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,25]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["BFleu20117"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.7","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,25]]},"assertion":[{"value":"13 April 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}